FDA Removes Breyanzi Limitation For CNS Lymphoma Patients
The update lets the CAR T-cell therapy reach lymphoma in the brain and spine. Its new safety data come from a cohort of five patients.
A five-patient cohort moved a federal label, and the label now reaches the patients CAR T trials spent years excluding.
The FDA has removed the label limitation that kept Breyanzi from patients whose lymphoma involves the central nervous system.
The November 2026 prescribing information deletes the limitation of use that excluded primary and secondary central nervous system lymphoma from the therapy's large B-cell lymphoma indications. It doesn't create a standalone indication for CNS lymphoma, and patients still qualify through the lymphoma label and its prior-treatment rules.
The safety case rests on a very small cohort. Study 6, a single-arm study coded JCAR017-BCM-001, treated five patients with relapsed or refractory primary CNS lymphoma. Cytokine release syndrome appeared in 60 percent of them, three of five, with no case at grade 3 or higher.
Neurologic toxicities appeared in 40 percent, two of five, with onset between 3 and 8 days and duration between 7 and 22 days. The events included seizure, headache, encephalopathy, and paresis. Five patients can show that a therapy isn't immediately prohibitive in this population, and they can't size the risk with any precision.
The therapy underneath the change is established. Liso-cel is a CD19-directed CAR T-cell therapy made from a patient's own cells, cleared for large B-cell lymphoma subtypes that include diffuse large B-cell, high-grade, primary mediastinal, and follicular lymphoma grade 3B. In the TRANSFORM trial its median event-free survival ran 10.1 months against 2.3 months on standard therapy.
Breyanzi is the second CAR T-cell therapy to clear this barrier. The FDA removed the same limitation from axicabtagene ciloleucel, sold as Yescarta, in February 2026. Breyanzi's boxed warnings stay in place, covering cytokine release syndrome, neurologic toxicities, and secondary blood cancers.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.